Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population

• Published in: PloS one Vol. 19; no. 4; p. e0299520
• Main Authors: Hernández-Bello, Jorge, Lorenzo-Leal, Ana C, Muñoz-Valle, José F, Morales-Núñez, José J, Díaz-Pérez, Saul A, Hernández-Gutiérrez, Rodolfo, Bach, Horacio
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 04.04.2024; Public Library of Science (PLoS)
• Subjects: Antibodies, Neutralizing; Antibodies, Viral; Biology and Life Sciences; COVID-19 - prevention & control; COVID-19 Vaccines; Humans; Medicine and Health Sciences; Methods; Mexico - epidemiology; Pandemics; SARS-CoV-2; Vaccination; Mexico
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0299520

During the COVID-19 pandemic, the Ad5-nCoV vaccine was applied to the Mexican population before the WHO approved it. In a transversal study, we compare the CanSino vaccine efficacy and a natural SARS-CoV-2 infection in eliciting neutralizing antibodies against the SARS-CoV-2 Delta variant in Guadalajara, Mexico. Participants between 30-60 years were included in the study and classified into three groups: 1) Natural immunity (unvaccinated), 2) Vaccine-induced immunity (vaccinated individuals without a COVID-19 history), and 3) Natural immunity + vaccine-induced immunity. These groups were matched by age and gender. We assessed the ability of individuals' serum to neutralize the Delta variant and compared the results of the different groups using a neutralization test followed by plaque-forming units. Results showed that 39% of individuals' serum with a history of COVID-19 (natural immunity, Group 1) could not neutralize the Delta variant, compared to 33% in vaccinated individuals without COVID-19 (vaccine immunity, Group 2). In contrast, only 7% of vaccinated individuals with a history of COVID-19 (natural + vaccine immunities) could not neutralize the Delta variant. We concluded that the effectiveness of the Ad5-nCoV vaccine to induce neutralizing antibodies against the Delta variant is comparable to that of natural infection (61% vs. 67%). However, in individuals with both forms of immunity (Group 3), it increased to 93%. Based on these results, despite the Ad5-nCoV vaccine originally being designed as a single-dose regimen, it could be recommended that even those who have recovered from COVID-19 should consider vaccination to boost their immunity against this variant.